Cerebral Infarction, Chronic Kidney Diseases, Mortality, Myocardial Infarction
Conditions
Brief summary
A registry of consecutive patients who were admitted and diagnosed with acute myocardial infarction or acute cerebral infarction were conducted at the Guangdong General Hospital or the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Yue Bei People's Hospital, China, between January 2000 and December 2016. The adverse clinical outcomes, including all-cause mortality, were followed from the date of admission for acute myocardial infarction or acute cerebral infarction until study end (December 31, 2016). All-cause mortality, including the date of death, was identified from the electronic hospitalization data, phone follow-up, and confirmed by the household registration (HUKOU) system, a record of registration required by law in China. Baseline characteristics, including major treatment of acute myocardial infarction or acute cerebral infarction, estimated glomerular filtration rate (eGFR) and proteinuria, were collected. Demographic data were determined from the electronic hospitalization data and electronic hospital discharge records. All comorbid conditions were identified using International Statistical Classification of Diseases, Tenth Revision (ICD-10), coding algorithms applied to electronic physician claims and electronic hospital discharge records. Life style (smoking), treatment regimen at discharge, including angiotensin-converting enzyme inhibitor (ACEI), angiotensin II receptor blocker (ARB), were determined from the electronic hospitalization data.
Interventions
None listed
Sponsors
Study design
Eligibility
Inclusion criteria
* consecutive patients who were admitted and diagnosed with acute myocardial infarction or acute cerebral infarction
Exclusion criteria
* lacunar infarction
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| all-cause mortality | follow up until the study end (May 2018,Anticipated) | all-cause mortality |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| kidney outcome | follow up until the study end (May 2018,Anticipated) | ESRD or 50%eGFR decline |
Countries
China